BEGIN:VCALENDAR
VERSION:2.0
PRODID:techtransfer.cancer.gov
BEGIN:VEVENT
UID:69d02fcb7ee61
DTSTART:20231212T160000Z
SEQUENCE:0
TRANSP:OPAQUE
DTEND:20231212T170000Z
SUMMARY:Technology Opportunity Webinar: Nestorone®/Testosterone Male Contr
 aceptive Gel
CLASS:PUBLIC
DESCRIPTION:In this free\, NIH webinar hosted by TTC\, attendees will learn
  about a first-of-its-kind male contraceptive hormonal gel\, Nestorone/Tes
 tosterone (NES/T)\, co-developed by the NICHD and Population Council throu
 gh the Contraceptive Clinical Trials Network (CCTN). This topical daily se
 lf-applied transdermal gel is designed to provide full sperm suppression w
 ithin 8-12 weeks and be reversible after 12-16 weeks of ending application
 . This presentation will showcase NES/T gel as an innovative user-controll
 ed option for male contraception. 
DTSTAMP:20260403T212323Z
END:VEVENT
END:VCALENDAR